Delving into the Latest Updates on Mural Oncology, Inc. with Synapse

A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

开始日期2021-09-27

申办/合作机构

Mural Oncology, Inc.

NCT04592653

/ Active, not recruiting临床1/2期

Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).

开始日期2020-09-30

申办/合作机构

Mural Oncology, Inc.

NCT04144517

/ Completed临床2期

A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission

The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.

开始日期2020-02-05

申办/合作机构

Mural Oncology, Inc.

[+1]

100 项与 Mural Oncology, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Mural Oncology, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Mural Oncology, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Mural Oncology, Inc. 相关的转化医学

登录后查看更多信息